Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence - 2Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
- 3Spots To Go Birdwatching All over the Planet
- 4Ski Resorts Universally: A Colder time of year Wonderland Guide
- 5Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- German unemployment rate falls to 6.4%, but 3 million still jobless
- Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- Full Supreme Court to hear challenge to Judicial Selection Committee law
- Fundamental Archives for Beginning Your Business
- NASA will bring space station crew home early after medical issue
- IDF strikes Hamas terror cell operating near Israeli troops in northern Gaza
- Instructions to Pick the Right Senior Protection Plan.
